Skip to main
  1. Stocks
  2. Supernus Inc
  3. Forecast
SUPN

Supernus Inc (SUPN) Stock Forecast & Price Target

Supernus Inc (SUPN) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Supernus is attractive because the combined company now markets 11 approved therapies across psychiatry, neurology, and addiction medicine, reducing dependence on any single asset while concentrating on durable CNS franchises. Its core growth drivers—Sublocade, Qelbree, Zurzuvae, and Onapgo—have clear commercial momentum and long exclusivity runways, and the cited model points to EBITDA comfortably north of $1B in 2027 with roughly $800M of net debt and only 6x-7x 2027 EBITDA valuation. The outlook is further supported by operating leverage from about $120M of annualized SG&A savings, plus meaningful upside from broadening LAI buprenorphine adoption and continued prescription growth in ADHD, PPD, and Parkinson’s disease.

Bears say

Supernus is facing a difficult mix of patent-cliff risk, competitive pressure, and execution uncertainty that weakens the durability of its earnings base. The disclosure that Gocovri is expected to peak at just over $175M in 2028, then face steep erosion after a June 2029 LOE, underscores how dependent the portfolio still is on a few products while generic competition already pressures the buprenorphine franchise, which has fallen from 20% in 2022 to 14.2% in 2025. Although the company has ongoing programs in depression, treatment-resistant epilepsy, and Parkinson’s disease hypomobility, FDA, commercialization, and financing risks could delay growth and require additional capital or partnerships.

Supernus Inc (SUPN) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Supernus Inc and is not a guaranteed prediction by Public.com or investment advice.

Supernus Inc (SUPN) Analyst Forecast & Price Prediction

Get the latest Supernus Inc (SUPN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Supernus Inc (SUPN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Supernus Inc (SUPN) Forecast

Analysts have given Supernus Inc (SUPN) a Buy based on their latest research and market trends.

According to 4 analysts, Supernus Inc (SUPN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Supernus Inc (SUPN)


Supernus Inc (SUPN) Analyst Forecast & Price Prediction

Get the latest Supernus Inc (SUPN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Supernus Inc (SUPN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SUPN stock data and trends